Watch Demo

New Zealand Antihypertensive Industry Outlook 2022 - 2026

See how New Zealand Antihypertensive performed compared to key markets such as Germany, Italy and Spain.

Key Market Indicators

New Zealand's antihypertensive medicine sales are on track to remain at $2.2 million by 2026, according to recent forecasts. Since 1998, demand for these medicines has increased by an average of 4% each year. In 2021, New Zealand was ranked 22nd in the world for antihypertensive medicine sales, with Portugal at the top of the list with $2.2 million. Italy, Spain and Australia followed in second, third and fourth place respectively.

New Zealand Antihypertensive Market Data and Forecasts

How much will New Zealand Antihypertensive Market grow to 2026?

Forecast: Antihypertensive Medicine Sales in New Zealand
Forecast: Antihypertensive Medicine Sales in New Zealand
Forecast: Antihypertensive Medicine Sales in New Zealand
Forecast: Renin-Angiotensin System Medicine Sales in New Zealand
Forecast: Antihypertensive Medicine Sales in New Zealand
More in Antihypertensive Industry for 2027

Improve your Knowledge with the latest Indicators and Trends